I-SPY 2: optimising cancer drug development in the 21st century

Yazar: Bartsch, Rupert, de Azambuja, Evandro
Yayımlandı ESMO Open (2016)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?

Yazar: Franzoi, Maria Alice, de Azambuja, Evandro
Yayımlandı ESMO Open (2020)

Threat posed by unproven drugs in medical oncology

Yazar: Pondé, Noam, Ades, Felipe, de Azambuja, Evandro
Yayımlandı ESMO Open (2016)

Phosphoethanolamine and the danger of unproven drugs

Yazar: Pondé, Noam, de Azambuja, Evandro, Ades, Felipe
Yayımlandı Ecancermedicalscience (2016)

Male breast cancer: finding the way in this uncommon path

Yazar: Maurer, Christian, Martel, Samuel, de Azambuja, Evandro
Yayımlandı ESMO Open (2017)

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?

Yazar: Poggio, Francesca, Lambertini, Matteo, de Azambuja, Evandro
Yayımlandı ESMO Open (2018)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

Yazar: Lambertini, Matteo, Viglietti, Giulia, de Azambuja, Evandro
Yayımlandı ESMO Open (2018)

How I treat metastatic triple-negative breast cancer

Yazar: Caparica, Rafael, Lambertini, Matteo, de Azambuja, Evandro
Yayımlandı ESMO Open (2019)

Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer

Yazar: Eiger, Daniel, Brandão, Mariana, de Azambuja, Evandro
Yayımlandı ESMO Open (2020)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

Yazar: Agostinetto, Elisa, Caparica, Rafael, de Azambuja, Evandro
Yayımlandı ESMO Open (2020)

Twenty years of anti-HER2 therapy-associated cardiotoxicity

Yazar: Pondé, Noam F, Lambertini, Matteo, de Azambuja, Evandro
Yayımlandı ESMO Open (2016)

How Long is Enough – Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer

Yazar: Pinto, Ana Catarina, de Azambuja, Evandro, Piccart-Gebhart, Martine
Baskı/Yayın Bilgisi 2013

Oncofertility counselling in premenopausal women with HER2-positive breast cancer

Yazar: Lambertini, Matteo, Demeestere, Isabelle, Viglietti, Giulia, de Azambuja, Evandro
Yayımlandı Oncotarget (2019)

The Exciting New Field of HER2-Low Breast Cancer Treatment

Yazar: Eiger, Daniel, Agostinetto, Elisa, Saúde-Conde, Rita, de Azambuja, Evandro
Yayımlandı Cancers (Basel) (2021)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

Yazar: Snoj, Natasa, Bedard, Philippe L, de Azambuja, Evandro, Cardoso, Fatima, Piccart, Martine
Baskı/Yayın Bilgisi 2009

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA

Yazar: Ades, Felipe, Senterre, Christelle, Zardavas, Dimitrios, de Azambuja, Evandro, Popescu, Razvan, Piccart, Martine
Yayımlandı PLoS One (2017)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

Yazar: Kourie, Hampig Raphael, El Rassy, Elie, Clatot, Florian, de Azambuja, Evandro, Lambertini, Matteo
Yayımlandı Onco Targets Ther (2017)

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives

Yazar: Caparica, Rafael, Lambertini, Matteo, Pondé, Noam, Fumagalli, Debora, de Azambuja, Evandro, Piccart, Martine
Yayımlandı Ther Adv Med Oncol (2019)

Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer

Yazar: Curigliano, Giuseppe, de Azambuja, Evandro, Lenihan, Daniel, Calabrò, Maria Grazia, Cardinale, Daniela, Cipolla, Carlo Maria
Yayımlandı Oncologist (2019)

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience

Yazar: Franzoi, Maria Alice, Saúde-Conde, Rita, Ferreira, Sofia Cristóvão, Eiger, Daniel, Awada, Ahmad, de Azambuja, Evandro
Yayımlandı Breast (2021)